RNA

Total RNA was prepared from cell line WM3629. WM3629 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a D549G mutation in the BRAF gene resulting in an amino acid substitution from aspartic acid to glycine at codon 549 (Asp549Gly). These cells also express G12D mutation in the N-RAS gene resulting in substitution of glycine with aspartic acid at codon 12 (Gly12Asp).WM3629 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3629. WM3629 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a D549G mutation in the BRAF gene resulting in an amino acid substitution from aspartic acid to glycine at codon 549 (Asp549Gly). These cells also express G12D mutation in the N-RAS gene resulting in substitution of glycine with aspartic acid at codon 12 (Gly12Asp).WM3629 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3630. WM3630 is a metastatic human melanoma cell line that displays a mesenchymal and fibroblastic morphology and form tight networks in culture. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses C70T (Cys70Thr) mutation in CDK4 gene and is wild type for N-RAS and c-KIT. WM3630 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3630. WM3630 is a metastatic human melanoma cell line that displays a mesenchymal and fibroblastic morphology and form tight networks in culture. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses C70T (Cys70Thr) mutation in CDK4 gene and is wild type for N-RAS and c-KIT. WM3630 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3630. WM3630 is a metastatic human melanoma cell line that displays a mesenchymal and fibroblastic morphology and form tight networks in culture. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses C70T (Cys70Thr) mutation in CDK4 gene and is wild type for N-RAS and c-KIT. WM3630 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3670. WM3670 is a metastatic human melanoma cell line with epithelial morphology. This cell line features the G469E mutation at codon 469 in the BRAF gene. The G469E mutation results in an amino acid substitution at position 469 in BRAF, from a glycine (G) to a glutamic acid (E). This mutation occurs within the highly conserved GXGXXG motif of the kinase domain. Most mutant BRAF proteins have increased kinase activity and are transforming in vitro. This cell line contains a G12D mutation at position 12 in the N-RAS gene. The G12D mutation results in an amino acid substitution at position 12 in N-RAS, from a glycine (G) to an aspartic acid (D).

Total RNA was prepared from cell line WM3670. WM3670 is a metastatic human melanoma cell line with epithelial morphology. This cell line features the G469E mutation at codon 469 in the BRAF gene. The G469E mutation results in an amino acid substitution at position 469 in BRAF, from a glycine (G) to a glutamic acid (E). This mutation occurs within the highly conserved GXGXXG motif of the kinase domain. Most mutant BRAF proteins have increased kinase activity and are transforming in vitro. This cell line contains a G12D mutation at position 12 in the N-RAS gene. The G12D mutation results in an amino acid substitution at position 12 in N-RAS, from a glycine (G) to an aspartic acid (D).

Total RNA was prepared from cell line WM3670. WM3670 is a metastatic human melanoma cell line with epithelial morphology. This cell line features the G469E mutation at codon 469 in the BRAF gene. The G469E mutation results in an amino acid substitution at position 469 in BRAF, from a glycine (G) to a glutamic acid (E). This mutation occurs within the highly conserved GXGXXG motif of the kinase domain. Most mutant BRAF proteins have increased kinase activity and are transforming in vitro. This cell line contains a G12D mutation at position 12 in the N-RAS gene. The G12D mutation results in an amino acid substitution at position 12 in N-RAS, from a glycine (G) to an aspartic acid (D).